Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol

Blood

Volumn 116, Issue 24, 2010, Pages 5140-5148

  Zhang, Qing Shuo ^a   Marquez Loza, Laura ^a   Eaton, Laura ^a   Duncan, Andrew W ^a   Goldman, Devorah C ^a,b   Anur, Praveen ^b,c   Watanabe Smith, Kevin ^a   Rathbun, R Keaney ^b,c   Fleming, William H ^a,d   Bagby, Grover C ^b,c   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RESVERATROL; SIRTUIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DEPRESSION; CELL CYCLE; COLONY FORMING UNIT S; CONTROLLED STUDY; FANCONI ANEMIA; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 78650042041     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-278226     Document Type: Article

References (49)

1. Moldovan GL, D'Andrea AD. How the Fanconi anemia pathway guards the genome. Annu Rev Genet. 2009;43:223-249.
2. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8(10): 735-748. (Pubitemid 47429206)
3. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249-1256. (Pubitemid 36182492)
4. -/- mice. EMBO J. 2005;24(4):861-871.
5. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature. 2007; 447(7145):725-729.
6. Ruzankina Y, Pinzon-Guzman C, Asare A, et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell. 2007; 1(1):113-126.
7. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol. 2006;43(3):147-156.
8. Du W, Adam Z, Rani R, Zhang X, Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal. 2008;10(11):1909-1921.
9. Muller LU, Williams DA. Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia. Mutat Res. 668(1-2):141-149, 2009.
10. Dufour C, Corcione A, Svahn J, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood. 2003;102(6):2053-2059.
11. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous over-production of tumor necrosis factor alpha. Blood. 1994;83(5):1216-1225. (Pubitemid 24062844)
12. Schultz JC, Shahidi NT. Tumor necrosis factor-alpha overproduction in Fanconi's anemia. Am J Hematol. 1993;42(2):196-201.
13. Rathbun RK, Faulkner GR, Ostroski MH, et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood. 1997; 90(3):974-985.
14. Li J, Sejas DP, Zhang X, et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest. 2007;117(11):3283-3295.
15. Li X, Yang Y, Yuan J, et al. Continuous in vivo infusion of interferon-gamma (IFN-gamma) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc-/- mice. Blood. 2004;104(4): 1204-1209.
16. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006;107(11):4223-4233.
17. Battaile KP, Bateman RL, Mortimer D, et al. In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Blood. 1999;94(6):2151-2158.
18. Carreau M, Gan OI, Liu L, Doedens M, Dick JE, Buchwald M. Hematopoietic compartment of Fanconi anemia group C null mice contains fewer lineage-negative CD34+ primitive hematopoietic cells and shows reduced reconstruction ability. Exp Hematol. 1999;27(11):1667-1674.
19. Haneline LS, Gobbett TA, Ramani R, et al. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood. 1999; 94(1):1-8.
20. Zhang QS, Eaton L, Snyder ER, et al. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res. 2008;68(5):1601-1608. (Pubitemid 351346870)
21. Houghtaling S, Timmers C, Noll M, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003;17(16):2021-2035.
22. Blom E, van de Vrugt HJ, de Winter JP, Arwert F, Joenje H. Evolutionary clues to the molecular function of fanconi anemia genes. Acta Haematol. 2002;108(4):231-236.
23. Timmers C, Taniguchi T, Hejna J, et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell. 2001;7(2):241-248.
24. Kalb R, Neveling K, Hoehn H, et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet. 2007;80(5):895-910.
25. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009;460(7255):587-591.
26. Guarente L, Picard F. Calorie restriction - the SIR2 connection. Cell. 2005;120(4):473-482.
27. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE. 2008;3(4):e2020.
28. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954): 191-196.
29. Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008;135(5):907-918.
30. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14(4):312-323.
31. Gao X, Xu YX, Divine G, Janakiraman N, Chapman RA, Gautam SC. Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr. 2002;132(7):2076-2081. (Pubitemid 34742903)
32. Willenbring H, Bailey AS, Foster M, et al. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med. 2004;10(7):744-748.
33. Wilson A, Murphy MJ, Oskarsson T, et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004;18(22):2747-2763.
34. Vanderwerf SM, Svahn J, Olson S, et al. TLR8- dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood. 2009;114(26): 5290-5298.
35. Auerbach AD, Liu Q, Ghosh R, Pollack MS, Douglas GW, Broxmeyer HE. Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion. 1990;30(8):682-687.
36. Bechtold A, Friedl R, Kalb R, et al. Prenatal exclusion/ confirmation of Fanconi anemia via flow cytometry: a pilot study. Fetal Diagn Ther. 2006; 21(1):118-124.
37. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature. 1981; 290(5802):142-143.
38. Sejas DP, Rani R, Qiu Y, et al. Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice. J Immunol. 2007;178(8):5277-5287.
39. Zhang X, Sejas DP, Qiu Y, Williams DA, Pang Q. Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J Cell Sci. 2007;120(Pt 9):1572-1583.
40. Liu TX, Howlett NG, Deng M, et al. Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev Cell. 2003;5(6):903-914.
41. Li Y, Chen S, Yuan J, et al. Mesenchymal stem/ progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo. Blood. 2009;113(10):2342-2351.
42. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet. 2008;9(2):115-128.
43. Hock H, Hamblen MJ, Rooke HM, et al. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature. 2004;431(7011):1002-1007. (Pubitemid 39434423)
44. Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006;441(7092):518-522.
45. Chambers SM, Boles NC, Lin KY, et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell. 2007;1(5):578-591.
46. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J. 2006; 397(3):519-527.
47. Sakata Y, Zhuang H, Kwansa H, Koehler RC, Dore S. Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp Neurol. 2010;224(1):325-329.
48. Yao J, Wang JY, Liu L, et al. Antioxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res. 2010;41(4):288-294.
49. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450(7170):712-716.